Van Tuyl Christopher Sells Shares of Immunovant, Inc.
Immunovant's Chief Legal Officer sold 2,634 shares, valued at $93,217.26.
Key Points
- Van Tuyl Christopher, Chief Legal Officer of Immunovant, Inc., sold 2,634 shares valued at $93,217.26 on June 18, 2026.
- Shares of Immunovant traded near $38.10 on Tuesday, with a market cap of about $7.82 billion and a 52-week high of $38.74.
- Analysts like Guggenheim and B of A Securities maintain 'buy' ratings, with target prices up to $62.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Van Tuyl Christopher, Chief Legal Officer of Immunovant, Inc. (NasdaqGS: IMVT), recently sold 2,634 shares of the company. The shares were sold at an average price of $35.39, resulting in a total transaction value of $93,217.26 on June 18, 2026. This transaction was not part of a pre-arranged trading plan.
Other Institutional Activity in Immunovant, Inc.
Several institutional investors have also been active in Immunovant, Inc. FMR LLC trimmed its holdings by 42,866 shares, bringing its total to 16,947,888 shares valued at approximately $420.99 million, a 0.3% decrease. Meanwhile, BlackRock, Inc. increased its position by 516,281 shares to a total of 6,574,497 shares worth about $163.31 million, marking an 8.5% increase. State Street Corp significantly boosted its stake by 751,003 shares, ending with 4,537,929 shares valued at $112.72 million, reflecting a 19.8% increase. TCG Crossover Management, LLC made a substantial addition of 2,797,055 shares, increasing its holdings by 168.4% to 4,457,988 shares valued at $110.74 million.
Immunovant, Inc. Stock Down 7.5%
Shares of Immunovant, Inc. traded near $38.10 on Tuesday. The company, with a market cap of approximately $7.82 billion, operates in the biotechnology industry. Immunovant has a forward P/E ratio of -15.64 and a beta of 0.79, indicating lower volatility compared to the market. The stock's 52-week range is between $14.32 and $38.74, with a 50-day moving average of $29.94 and a 200-day moving average of $24.73. The company maintains a strong financial position, with a current ratio of 9.09 and a very low debt-to-equity ratio of 0.008.
$IMVT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been actively updating their price targets for Immunovant, Inc. On May 26, 2026, Guggenheim maintained its 'buy' rating with a target price of $62.00. Truist Securities kept a 'hold' rating with a $30.00 target on May 22, 2026. B of A Securities also maintained a 'buy' rating, setting a target price of $43.00 on May 21, 2026. The consensus among analysts is a 'buy' rating, with an average target price of $45.76 among 17 opinions.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biotechnology company based in Durham, North Carolina. It focuses on developing targeted therapies to address autoimmune diseases. The company's lead product, IMVT-1402, is a monoclonal antibody designed to inhibit a specific receptor involved in various autoimmune conditions, including Graves' disease and rheumatoid arthritis. Founded in 2018, Immunovant operates as a subsidiary of Roivant Sciences Ltd.
Bottom Line
Immunovant, Inc. is on the radar of investors and analysts alike. With insider sales like that of Van Tuyl Christopher, market participants keep a close watch on such moves as part of broader investment strategies. Institutional activity and analyst ratings provide a snapshot of sentiment around this biotech firm. As always, 13F filings are backward-looking and do not necessarily reflect current holdings.
Get Immunovant, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMVT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.